Is resveratrol an estrogen agonist in growing rats?

Endocrinology

Volumn 140, Issue 1, 1999, Pages 50-54

  Turner, Russell T ^a,b   Evans, Glenda L ^a   Zhang, Minzhi ^a   Maran, Avudaiappan ^a   Sibonga, Jean D ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTRADIOL; ESTROGEN RECEPTOR; RESVERATROL; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BODY WEIGHT; BONE GROWTH; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; GROWTH ACCELERATION; GROWTH RATE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE; RNA ANALYSIS; STATISTICAL ANALYSIS; STEADY STATE; UTERUS WEIGHT;

EID: 0032940535     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.1.6460     Document Type: Article

References (25)

1. 1. Celotti E, Ferrarini R, Zironi R, Conte LS 1996 Resveratrol content of some wines obtained from dried Valpolicella grapes: recioto and Amarone. J Chromatogr [A] 730:47-52
2. 2. Sato M, Suzuki Y, Okuda T, Yokotsuka K 1997 Contents of resveratrol, piceid, and their isomers in commercially available wines made from grapes cultivated in Japan. Biosci Biotechnol Biochem 61:1800-1805
3. 3. Mattivi F 1993 Solid phase extraction of trans-resveratrol from wines for HPLC analysis. Z Lebensm Unters Forsch 196:522-525
4. 4. Bertelli AAE, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, Bertelli A 1995 Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 17:1-3
5. 5. Goldberg DM, Hahn SE, Parkes JG 1995 Beyond alcohol: beverage consumption and cardiovascular mortality. Clin Chim Acta 237:155-187
6. 6. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM 1995 The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235:207-219
7. 7. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP, Goldberg DM 1996 Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 246:163-182
8. 8. Goldberg DM, Garovic-Kocic V, Diamandis EP, Pace-Asciak CR 1996 Wine: does the colour count? Clin Chim Acta 246:183-193
9. 9. Wilson T, Knight TJ, Beitz DC, Lewis DS, Engen RL 1996 Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 59:PL15-PL21
10. 10. Gehm BD, McAndrews JM, Chien P-Y, Jameson JL 1997 Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94:14138-14143
11. 11 Jimenez MA, Magee DE, Bryant HU, Turner RT 1997 Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats. Endocrinology 138:1794-1800
12. 12. Westerlind KC, Gibson KJ, Malone P, Evans GL, Turner RT 1998 Differential effects of estrogen metabolites on bone and reproductive tissues of ovariectomized rats. J Bone Miner Res 13:1023-1031
13. 13. Westerlind KC, Sarkar G, Bolander ME, Turner RT 1995 Estrogen receptor mRNA is expressed in vivo in rat calvarial periosteum. Steroids 60:484-487
14. 14. Cavolina JM, Evans GL, Harris SA, Zhang M, Westerlind KC, Turner RT 1997 The effects of orbital spaceflight on bone histomorphometry and mRNA levels for bone matrix proteins and skeletal signaling peptides in ovariectomized growing rats. Endocrinology 138:1567-1576
15. 1,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res 16:77-81
16. 16. Bertelli AAE, Giovannini L, Stradi R, Bertelli A, Tillement J-P 1996 Plasma, urine and tissue levels of trans-and cis-resveratrol (3,4,5-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int J Tissue React 18:67-71
17. 17. Kannel WB, Ellison RC 1996 Alcohol and coronary heart disease: the evidence for a protective effect. Clin Chim Acta 246:59-76
18. 18. Turner RT, Vandersteenhoven JJ, Bell NH 1987 The effects of ovariectomy and 17β-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2:115-122.
19. 19 Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69.
20. 20. Murphy LJ, Murphy JW 1994 Steroid hormone induction of growth factors and oncogene expression in the uterus. In: Khan SA, Stancel GM (eds) Proto-Oncogenes and Growth Factors in Steroid Hormone Induced Growth and Differentiation. CRC Press, Boca Raton, pp 31-45
21. 21. Evans GL, Turner RT 1995 Tissue selective actions on estrogen analogs. Bone 17:181S-190S
22. 22. Kauffman RF, Bensch WR, Roudebush RE, Cole HW, Bean JS, Phillips DL, Monroe A, Cullinan GJ, Glasebrook AL, Bryant HU 1997 Hypocholesterolemic activity of raloxifene (LY139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 280:146-153
23. 23. Sibonga JD, Dobnig H, Harden RM, Turner RT 1998 Effect of the high affinity estrogen receptor ligand ICI 182,780 on rat tibia. Endocrinology 139:3736-3742
24. 24. Weinstein I, Wilcox HG, Heimberg M 1986 Effects of high-dose ethinyl estradiol on serum concentrations and hepatic secretion of the very-low-density lipoprotein, triacylglycerol, cholesterol, and apolipoprotein A-I in the rat. Biochim Biophys Acta 876:450-459
25. 25. Turner RT, Riggs BL, Spelsberg TC 1994 Skeletal effects of estrogen. Endocr Rev 15:275-300